Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), Rallis India has informed that the Board of Directors of the company, at its meeting held on January 17, 2019, has considered and approved the proposal for the merger of Metahelix Life Sciences ('Transferor Company'), a wholly owned subsidiary of the company, with Rallis lndia ('the Company' or 'Transferee Company') and their Shareholders and Creditors, under Sections 230 to 234 of the Companies Act, 2013 and other provisions of the Companies Act 2013 (including any statutory modification or reenactment or amendment thereof) as per the terms and conditions mentioned in the Scheme of Merger by Absorption ('Scheme') placed before the Board. The merger is subject to the necessary approvals/ sanctions, from the jurisdictional National Company Law Tribunal(s) or such other competent authority and shareholders and creditors of the Transferor and Transferee Company, if applicable. The details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated 9th September, 2015, with respect to the above, are given in the enclosed Annexure. The Board of Directors at the same meeting has also approved the proposal to voluntarily file an application with the Registrar of Companies for removal of the name of Rallis Chemistry Exports, a non-operational wholly owned subsidiary of the company which has no intention to carry on any business, from the Register of Companies, subject to necessary regulatory and other approvals.
The above information is a part of company’s filings submitted to BSE.